FIELD: medicine.
SUBSTANCE: what is offered is applying an analysis of p53(TP53) gene status and/or expression level as a biomarker while evaluating sensitivity of an individual suffering a proliferative disease to treatment by an mTOR inhibitor combined with a cytotoxic agent or while selecting individuals sensitive to the specified combined therapy for the following treatment of the disease by this method. Thus sensitivity to treatment of the proliferative disease by the mTOR inhibitor combined with the cytotoxic agent is predicted if wild-type functionally active p53 gene is found in a sample taken from the patient.
EFFECT: higher analysis accuracy.
14 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIOMARKER | 2005 |
|
RU2385944C2 |
| TREATING NEUROENDOCRINE TUMOURS | 2006 |
|
RU2487711C2 |
| COMBINATIONS OF THERAPEUTIC AGENTS APPLICABLE FOR TREATING CANCER | 2007 |
|
RU2447891C2 |
| GENE TRANSITION MEDIATED BY LENTIVIRAL VECTOR AND METHOD FOR USING THE GENES | 2001 |
|
RU2288742C2 |
| COMPOSITION FOR TREATMENT OF CANCER ASSOCIATED WITH HPV INFECTION | 2013 |
|
RU2636003C2 |
| THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR BLADDER CANCER | 2015 |
|
RU2739942C2 |
| BIOMARKERS PREDICTING A THERAPEUTIC RESPONSE TO THERAPY WITH A CHIMERIC ANTIGEN RECEPTOR, AND USE THEREOF | 2015 |
|
RU2743657C2 |
| USE OF MYOSTATIN ANTAGONISTS, COMBINATION CONTAINING THEM AND THEIR USE | 2016 |
|
RU2781401C2 |
| COMBINATION OF PHOSPHATIDYL INOSITOL-3-KINASE (PI3K) INHIBITOR AND mTOR INHIBITOR | 2009 |
|
RU2538683C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
